Effects of angiotensin ii type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis

Nephron - Clinical Practice

Volumn 112, Issue 1, 2009, Pages

  Shigenaga, Atsu Ichiro ^a   Tamura, Kouichi ^a   Dejima, Toru ^a   Ozawa, Motoko ^a   Wakui, Hiromichi ^a   Masuda, Shin Ichiro ^a   Azuma, Koichi ^a   Tsurumi Ikeya, Yuko ^a   Mitsuhashi, Hiroshi ^a   Okano, Yasuko ^a   Kokuho, Toshiharu ^a   Sugano, Teruyasu ^a   Ishigami, Tomoaki ^a   Toya, Yoshiyuki ^a   Uchino, Kazuaki ^a   Tokita, Yasuo ^b   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Fujisawa Municipal Hospital   (Japan)

Author keywords

Ambulatory blood pressure monitoring; Angiotensin II receptor antagonist; Brain natriuretic peptide; Continuous ambulatory peritoneal dialysis; Hypertension; Left ventricular hypertrophy; Remodeling

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; NATRIURETIC FACTOR; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE VARIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PULSE WAVE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CIRCADIAN RHYTHM; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PULSE; TETRAZOLES; VALINE; VENTRICULAR REMODELING;

EID: 63349087761     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210572     Document Type: Article

References (49)

1. Floras JS, Hassan MO, Jones JV, Osikowska BA, Sever PS, Sleight P: Factors influencing blood pressure and heart rate variability in hypertensive humans. Hypertension 1988;11:273-281.
2. Pickering TG: Variability of blood pressure. Blood Press Monit 1998;3:141-145.
3. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, Grassi G, Di Rienzo M, Pedotti A, Zanchetti A: Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983;53:96-104.
4. Mancia G, Parati G: Ambulatory blood pressure monitoring and organ damage. Hypertension 2000;36:894-900.
5. Imai Y: Prognostic significance of ambulatory blood pressure. Blood Press Monit 1999;4:249-256.
6. Parati G, Di Rienzo M, Mancia G: Neural cardiovascular regulation and 24-hour blood pressure and heart rate variability. Ann NY Acad Sci 1996;783:47-63.
7. Laitinen T, Hartikainen J, Niskanen L, Geelen G, Lansimies E: Sympathovagal balance is major determinant of short-term blood pressure variability in healthy subjects. Am J Physiol 1999;276:H1245-H1252.
8. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G: Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987;5:93-98.
9. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G: Prognostic value of 24-hour blood pressure variability. J Hypertens 1993;11:1133-1137.
10. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, Costa B, Scherz R, Bond G, Zanchetti A: Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001;19:1981-1989.
11. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B: Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000;102:1536-1541.
12. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y: Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000;36:901-906.
13. Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, Giacone G, Cottini E, Tripepi G, Malatino LS, Zoccali C: Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001;16:1459-1464.
14. Zoccali C, Mallamaci F, Tripepi G: Hypertension as a cardiovascular risk factor in end-stage renal failure. Curr Hypertens Rep 2002;4:381-386.
15. Velasquez MT, Lew SQ, von Albertini B, Mishkin GJ, Bosch JP: Control of hypertension is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients. Clin Nephrol 1997;48:341-345.
16. Takeda K, Nakamoto M, Hirakata H, Baba M, Kubo M, Fujishima M: Disadvantage of long-term CAPD for preserving cardiac performance: an echocardiographic study. Am J Kidney Dis 1998;32:482-487.
17. Cocchi R, Degli Esposti E, Fabbri A, Lucatello A, Sturani A, Quarello F, Boero R, Bruno M, Dadone C, Favazza A, Scanziani R, Tommasi A, Giangrande A: Prevalence of hypertension in patients on peritoneal dialysis: results of an Italian multicentre study. Nephrol Dia l Tra nsplant 1999;14:1536-1540.
18. Spallone V, Bernardi L, Ricordi L, Solda P, Maiello MR, Calciati A, Gambardella S, Fratino P, Menzinger G: Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 1993;42:1745-1752.
19. Tochikubo O, Ikeda A, Miyajima E, Ishii M: Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hy pertension 1996;27:1318-1324.
20. Yasuda G, Hasegawa K, Kuji T, Ogawa N, Shimura G, Umemura S, Tochikubo O: Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy. Am J Hypertens 2004;17:14-20.
21. Tamura K, Yamauchi J, Tsurumi-Ikeya Y, Sakai M, Ozawa M, Shigenagal A, Azuma K, Okano Y, Ishigami T, Toya Y, Yabana M, Tokita Y, Ohnishi T, Umemura S: Ambulatory blood pressure and heart rate in hypertensives with renal failure: comparison between diabetic nephropathy and non-diabetic glomeru lopathy. Clin Exp Hypertens 2008;30:33-43.
22. Eto M, Toba K, Akishita M, Kozaki K, Watanabe T, Kim S, Hashimoto M, Ako J, Iijima K, Sudoh N, Yoshizumi M, Ouchi Y: Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hyper tens Res 2005;28:1-7.
23. Sakai M, Tamura K, Tanaka Y, Tsurumi Y, Okano Y, Koide Y, Endoh T, Matsushita K, Kihara M, Hirawa N, Toya Y, Tokita Y, Ohnishi T, Umemura S: Analysis of factors that affect short-term blood pressure variability in patients with chronic renal failure. Clin Exp Hyper tens 2005;27:139-147.
24. Tamura K, Tsurumi Y, Sakai M, Tanaka Y, Okano Y, Yamauchi J, Ishigami T, Kihara M, Hirawa N, Toya Y, Yabana M, Tokita Y, Ohnishi T, Umemura S: A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 2007;29:31-42.
25. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y: Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002;25:359-364.
26. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-618.
27. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB: Relation of blood pressure variability to carotid atherosclerosis and carotid artery and left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 2001;21:1507-1511.
28. Mancia G, Grassi G: Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol 2000;35:S15-S19.
29. Mancia G, Di Rienzo M, Parati G, Grassi G: Sympathetic activity, blood pressure variability and end organ damage in hypertension. J Hum Hypertens 1997;11(s u p p l 1) : S 3-S8.
30. Narkiewicz K, Winnicki M, Schroeder K, Phillips BG, Kato M, Cwalina E, Somers VK: Relationship between muscle sympathetic nerve activity and diurnal blood pressure profile. Hypertension 2002;39:168-172.
31. Sega R, Corrao G, Bombelli M, Beltrame L, Facchett i R, Gra ssi G, Ferr a rio M, Ma nc ia G: Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002;39:710-714.
32. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-1918.
33. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-1979.
34. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105:1354-1359.
35. Matayoshi T, Kato T, Nakahama H, Nakata H, Yoshihara F, Kamide K, Horio T, Nakamura S, Kawano Y: Brain natriuretic peptide in hemodialysis patients: predictive value for hemodynamic change during hemodialysis and cardiac function. Am J Nephrol 2008;28:122-127.
36. Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M, Toba K: Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis 2004;173:13-18.
37. 2+-leak induced by oxidative stress. Circ J 2006;70:777-786.
38. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T: Angiotensin II type 1receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002;90:256-261.
39. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R: Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008;52:501-506.
40. Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J: Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 2006;21:16-20.
41. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H: Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004;43:1056-1064.
42. Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte J, Salvador M, Chamontin B: Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000;57:2485-2491.
43. Liu M, Takahashi H, Morita Y, Maruyama S, Mizuno M, Yuzawa Y, Watanabe M, Toriyama T, Kawahara H, Matsuo S: Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant 2003;18:563-569.
44. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
45. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553.
46. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-2092.
47. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
48. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.
49. Ohishi M, Takagi T, Ito N, Tatara Y, Hayashi N, Shiota A, Iwamoto Y, Katsuya T, Rakugi H, Ogihara T: Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study. Hy pertens Res 2007;30:1187-1192.